[go: up one dir, main page]

RU94040361A - AEROSOL PHARMACEUTICAL COMPOSITION, SPRAYER FOR DELIVERY OF THE COMPOSITION, DOSAGE INHALATOR, METHOD FOR TREATING RESPIRATORY DISEASES, METHOD FOR PRODUCING THE COMPOSITION - Google Patents

AEROSOL PHARMACEUTICAL COMPOSITION, SPRAYER FOR DELIVERY OF THE COMPOSITION, DOSAGE INHALATOR, METHOD FOR TREATING RESPIRATORY DISEASES, METHOD FOR PRODUCING THE COMPOSITION

Info

Publication number
RU94040361A
RU94040361A RU94040361/14A RU94040361A RU94040361A RU 94040361 A RU94040361 A RU 94040361A RU 94040361/14 A RU94040361/14 A RU 94040361/14A RU 94040361 A RU94040361 A RU 94040361A RU 94040361 A RU94040361 A RU 94040361A
Authority
RU
Russia
Prior art keywords
composition according
composition
propellant
paragraphs
beclomethasone dipropionate
Prior art date
Application number
RU94040361/14A
Other languages
Russian (ru)
Other versions
RU2120285C1 (en
Inventor
Джон Нил Филип
Джеймс Тэйлор Энтони
Original Assignee
Глэксо Груп Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929202519A external-priority patent/GB9202519D0/en
Application filed by Глэксо Груп Лимитед filed Critical Глэксо Груп Лимитед
Publication of RU94040361A publication Critical patent/RU94040361A/en
Application granted granted Critical
Publication of RU2120285C1 publication Critical patent/RU2120285C1/en

Links

Claims (20)

1. Фармацевтическая аэрозольная композиция, отличающаяся тем, что включает: (а) моногидрат беклометазондипропионата с размером частиц в основном менее 20 мкм; (в) по крайней мере 0,015% воды от массы композиции в дополнение к кристаллизационной воде, связанной в моногидрате и (с) фторуглеродный или содержащий водород хлорфтоуглеродный пропеллент.1. A pharmaceutical aerosol composition, characterized in that it includes: (a) beclomethasone dipropionate monohydrate with a particle size of substantially less than 20 microns; (c) at least 0.015% of the water by weight of the composition in addition to crystallization water bound in the monohydrate; and (c) a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant. 2. Фармацевтическая аэрозольная композиция, отличающаяся тем, что состоит в основном из моногидрата беклометазондипропионата, по крайней мере 0,015 мас. % и одного или более фторуглеродных или содержащих водород хлорфторуглеродных носителей. 2. Pharmaceutical aerosol composition, characterized in that it consists mainly of beclomethasone dipropionate monohydrate, at least 0.015 wt. % and one or more fluorocarbon or hydrogen-containing chlorofluorocarbon carriers. 3. Композиция по п. 1 или 2, отличающаяся тем, что включает от 0,015 по 0,1 мас.% добавленной воды. 3. The composition according to p. 1 or 2, characterized in that it comprises from 0.015 to 0.1 wt.% Added water. 4. Композиция по любому из пп. 1 - 3, отличающаяся тем, что включает по крайней мере 0,026 мас.% добавленной воды. 4. The composition according to any one of paragraphs. 1 to 3, characterized in that it includes at least 0.026 wt.% Added water. 5. Композиция по любому из пп. 1 - 4, отличающаяся тем, что включает от 0,026 до 0,08 мас.% добавленной воды. 5. The composition according to any one of paragraphs. 1 to 4, characterized in that it includes from 0.026 to 0.08 wt.% Added water. 6. Композиция по любому из пп. 1 - 5, отличающаяся тем, что носитель включает С1-4-фторуглерод, содержащий водород.6. The composition according to any one of paragraphs. 1 to 5, characterized in that the carrier comprises a C 1-4 fluorocarbon containing hydrogen. 7. Композиция по п. 6, отличающаяся тем, что носитель включает 1,1,1,2,3,3,3-гептафтор-н-пропан. 7. The composition according to p. 6, characterized in that the carrier comprises 1,1,1,2,3,3,3-heptafluoro-n-propane. 8. Композиция по п. 6, отличающаяся тем, что пропеллент включает 1,1,1,2-тетрафторэтан. 8. The composition according to p. 6, characterized in that the propellant includes 1,1,1,2-tetrafluoroethane. 9. Композиция по п. 1 или 2, отличающаяся тем, что включает от 0,03 до 0,08 мас.% добавленной воды и 1,1,1,2-тетрафторэтан в качестве пропеллента. 9. The composition according to p. 1 or 2, characterized in that it comprises from 0.03 to 0.08 wt.% Added water and 1,1,1,2-tetrafluoroethane as a propellant. 10. Композиция по п. 1 или 2, отличающаяся тем, что включает от 0,02 до 0,05 мас. % добавленной воды и 1,1,1,2,3,3,3-гептафтор-н-пропан в качестве пропеллента. 10. The composition according to p. 1 or 2, characterized in that it includes from 0.02 to 0.05 wt. % added water and 1,1,1,2,3,3,3-heptafluoro-n-propane as a propellant. 11. Композиция по любому из пп. 1 - 10, отличающаяся тем, что моногидрат беклометазондипропионата присутствует в количестве от 0,005 до 10% (мас. /мас.) от общей массы композиции. 11. The composition according to any one of paragraphs. 1 to 10, characterized in that beclomethasone dipropionate monohydrate is present in an amount of from 0.005 to 10% (w / w) of the total weight of the composition. 12. Композиция по любому из пп. 1 - 11, отличающаяся тем, что содержит один или более дополнительных активных ингредиентов. 12. The composition according to any one of paragraphs. 1 to 11, characterized in that it contains one or more additional active ingredients. 13. Композиция по п. 12, отличающаяся тем, что включает салметерол или салбутамол или их фармацевтически пригодную соль в комбинации с моногидратом беклометазондипропионата. 13. The composition according to p. 12, characterized in that it comprises salmeterol or salbutamol or a pharmaceutically acceptable salt thereof in combination with beclomethasone dipropionate monohydrate. 14. Композиция по п. 13, отличающаяся тем, что включает салбутамол и моногидрат беклометазондипропионата. 14. The composition according to p. 13, characterized in that it includes salbutamol and beclomethasone dipropionate monohydrate. 15. Композиция по п. 13, отличающаяся тем, что включает ксинофоат сальметерола и моногидрат беклометазондипропионата. 15. The composition according to p. 13, characterized in that it comprises salmeterol xinophoate and beclomethasone dipropionate monohydrate. 16. Композиция по любому из пп. 1 - 15, отличающаяся тем, что вдыхаемая фракция составляет 20% или более лекарственного средства. 16. The composition according to any one of paragraphs. 1 to 15, characterized in that the respirable fraction is 20% or more of the drug. 17. Баллончик, подходящий для доставки фармацевтической аэрозольной композиции, отличающийся тем, что включает контейнер, способный выдерживать давление используемого пропеллента, указанный контейнер закрыт дозировочным клапаном и содержит фармацевтическую аэрозольную композицию, состоящую из: (а) моногидрата беклометазондипропионата, размер частиц которого в основном менее 20 мкм; (b) по крайней мере 0,015 мас.% воды от массы композиции в дополнение к кристаллизационной воде, связанной в указанном моногидрате и (с) фторуглеродный или содержащий водород хлорфторуглеродный пропеллент. 17. A canister suitable for delivering a pharmaceutical aerosol composition, characterized in that it includes a container capable of withstanding the pressure of the propellant used, said container is closed by a metering valve and contains a pharmaceutical aerosol composition consisting of: (a) beclomethasone dipropionate monohydrate, the particle size of which is generally less than 20 microns; (b) at least 0.015 wt.% water by weight of the composition in addition to crystallization water bound in said monohydrate; and (c) a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant. 18. Дозировочный ингалятор, отличающийся тем, что включает баллончик по п. 17, снабженный подходящим устройством с системой каналов. 18. A metered-dose inhaler, characterized in that it includes a can according to claim 17, equipped with a suitable device with a channel system. 19. Способ лечения респираторных заболеваний, отличающийся тем, что включает введение путем ингаляции эффективного количества фармацевтической аэрозольной композиции, состоящей из: (а) моногидрата беклометазондипропионата, размер частиц которого в основном менее 20 мкм; (b) по крайней мере 0,015% воды от массы композиции в дополнение к кристаллизационной воде, связанной в указанном моногидрате, и (с) фторуглеродный или содержащий водород хлорфторуглеродный пропеллент. 19. A method of treating respiratory diseases, characterized in that it comprises administering by inhalation an effective amount of a pharmaceutical aerosol composition consisting of: (a) beclomethasone dipropionate monohydrate, the particle size of which is generally less than 20 microns; (b) at least 0.015% of the water by weight of the composition in addition to the crystallization water bound in said monohydrate; and (c) a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant. 20. Способ получения фармацевтической аэрозольной композиции по любому из пп. 1 - 16, отличающийся тем, что включает диспергирование лекарственного средства и добавленной воды в пропелленте. 20. A method of obtaining a pharmaceutical aerosol composition according to any one of paragraphs. 1 to 16, characterized in that it includes the dispersion of the drug and the added water in the propellant.
RU94040361A 1992-02-06 1993-02-02 Aerosol pharmaceutic composition, bottle for storage and delivery of aerosol pharmaceutic composition, method of treatment of respiratory diseases, composition preparation method RU2120285C1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9202519.6 1992-02-06
GB929202519A GB9202519D0 (en) 1992-02-06 1992-02-06 Medicaments

Publications (2)

Publication Number Publication Date
RU94040361A true RU94040361A (en) 1998-02-10
RU2120285C1 RU2120285C1 (en) 1998-10-20

Family

ID=10709929

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94040361A RU2120285C1 (en) 1992-02-06 1993-02-02 Aerosol pharmaceutic composition, bottle for storage and delivery of aerosol pharmaceutic composition, method of treatment of respiratory diseases, composition preparation method

Country Status (30)

Country Link
US (2) US5695744A (en)
EP (1) EP0625046B1 (en)
JP (1) JP3675474B2 (en)
CN (1) CN1048394C (en)
AP (1) AP419A (en)
AT (1) ATE157875T1 (en)
AU (1) AU667074B2 (en)
BG (1) BG61862B1 (en)
CA (1) CA2128688A1 (en)
CZ (1) CZ281942B6 (en)
DE (1) DE69313825T2 (en)
DK (1) DK0625046T3 (en)
ES (1) ES2106360T3 (en)
GB (1) GB9202519D0 (en)
GE (1) GEP19991820B (en)
GR (1) GR3025363T3 (en)
HU (2) HUT68986A (en)
IL (1) IL104628A (en)
IS (1) IS1622B (en)
MX (1) MX9300620A (en)
MY (1) MY108748A (en)
NO (1) NO306453B1 (en)
NZ (1) NZ246889A (en)
OA (1) OA10091A (en)
RO (1) RO118173B1 (en)
RU (1) RU2120285C1 (en)
SK (1) SK279291B6 (en)
TW (1) TW299234B (en)
WO (1) WO1993015741A1 (en)
ZA (1) ZA93800B (en)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919435A (en) * 1990-11-09 1999-07-06 Glaxo Group Limited Aerosol formulation containing a particulate medicament
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
AU663905B2 (en) 1991-12-12 1995-10-26 Glaxo Group Limited Medicaments
DE69232034T2 (en) 1991-12-18 2002-06-06 Minnesota Mining And Mfg. Co., Saint Paul Aerosol compositions for drug suspensions
US7105152B1 (en) 1991-12-18 2006-09-12 3M Innovative Properties Company Suspension aerosol formulations
US7101534B1 (en) 1991-12-18 2006-09-05 3M Innovative Properties Company Suspension aerosol formulations
US5833950A (en) * 1992-07-31 1998-11-10 Glaxo Group Limited Aerosol formulations containing beclomethasone dipropionate-1, 1, 1, 2-tetrafluoroethane solvate
GB9404945D0 (en) * 1994-03-15 1994-04-27 Glaxo Group Ltd Pharmaceutical composition
EE9700138A (en) * 1994-12-22 1997-12-15 Astra Aktiebolag Aerosol formulations
US6013245A (en) * 1995-01-26 2000-01-11 Glaxo Group Limited Aerosol formulation containing beclomethasone dipropionate and 1,1,1,2,3,3,3-heptafluoro-n-propane as propellant
US5874481A (en) * 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
MX9800125A (en) 1995-06-27 1998-03-31 Boehringer Ingelheim Kg New, stable medicinal compositions for generating propellant-free aerosols.
HU224224B1 (en) * 1997-01-14 2005-06-28 Lts Lohmann Therapie-Systeme Gmbh Expandable gastro-retentive therapeutic system with controlled active substance release in the gastro-intestinal tract
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
TR199902615T2 (en) * 1997-03-18 2000-03-21 Basf Aktiengesellschaft Methods and compositions for modulating the response to corticosteroids.
US5891419A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe flunisolide aerosol formulations for oral inhalation
US6129905A (en) * 1997-04-21 2000-10-10 Aeropharm Technology, Inc. Aerosol formulations containing a sugar as a dispersant
US5891420A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe triancinolone acetonide aerosol formulations for oral inhalation
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6946117B1 (en) 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6598603B1 (en) * 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
US6086376A (en) * 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
WO1999044594A1 (en) * 1998-03-05 1999-09-10 Nippon Shinyaku Co., Ltd. Fat emulsions for inhalational administration
TWI243687B (en) * 1998-04-21 2005-11-21 Teijin Ltd Pharmaceutical composition for application to mucosa
US6458338B1 (en) 1998-09-22 2002-10-01 Aeropharm Technology Incorporated Amino acid stabilized medicinal aerosol formulations
US6136294C1 (en) * 1998-09-22 2002-09-24 Aeropharm Technology Inc Amino acid stabilized medical aerosol formulation
IT1303692B1 (en) * 1998-11-03 2001-02-23 Chiesi Farma Spa PROCEDURE FOR THE PREPARATION OF SUSPENSIONS OF PARTICLES OF DRUGS TO BE ADMINISTERED BY INHALATION.
US20060171899A1 (en) * 1998-12-10 2006-08-03 Akwete Adjei Water-stabilized aerosol formulation system and method of making
US7074388B2 (en) * 1998-12-10 2006-07-11 Kos Life Science, Inc. Water stabilized medicinal aerosol formulation
US6261539B1 (en) * 1998-12-10 2001-07-17 Akwete Adjei Medicinal aerosol formulation
US6540983B1 (en) 2000-01-25 2003-04-01 Aeropharm Technology Incorporated Medical aerosol formulation
US6540982B1 (en) 2000-01-25 2003-04-01 Aeropharm Technology Incorporated Medical aerosol formulation
US6548049B1 (en) 2000-05-01 2003-04-15 Aeropharm Technology Incorporated Medicinal aerosol formulation
US6565833B1 (en) 2000-05-01 2003-05-20 Aeropharm Technology Incorporated Medicinal aerosol formulation
US6447750B1 (en) 2000-05-01 2002-09-10 Aeropharm Technology Incorporated Medicinal aerosol formulation
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
PT1280520E (en) 2000-05-10 2014-12-16 Novartis Ag Phospholipid-based powders for drug delivery
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
WO2002007672A2 (en) * 2000-07-19 2002-01-31 Aeropharm Technology, Inc. A medicinal aerosol formulation
AU2001278115A1 (en) * 2000-08-04 2002-02-18 Longwood Pharmaceutical Research, Inc. Formulations of mometasone and a bronchodilator for pulmonary administration
US6455028B1 (en) 2001-04-23 2002-09-24 Pharmascience Ipratropium formulation for pulmonary inhalation
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
WO2003053411A1 (en) 2001-12-19 2003-07-03 Nektar Therapeutics Pulmonary delivery of aminoglycosides
EP1415647A1 (en) * 2002-10-23 2004-05-06 CHIESI FARMACEUTICI S.p.A. "Long-acting beta-2 agonists ultrafine formulations"
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
AU2007231727B2 (en) * 2002-09-03 2010-12-16 Kos Life Sciences, Inc. Water stabilized medicinal aerosol formulation
HRP20050822B1 (en) * 2003-03-20 2013-09-30 Boehringer Ingelheim Pharmaceuticals Inc. Formulation for a metered dose inhaler using hydro-fluoro-alkanes as propellants
US20040191176A1 (en) * 2003-03-28 2004-09-30 Kaplan Leonard W Formulations for treatment of pulmonary disorders
US20080190418A1 (en) * 2003-08-29 2008-08-14 Glaxo Group Limited Pharmaceutical Metered Dose Inhaler and Methods Relating Thereto
AR041873A1 (en) * 2003-10-30 2005-06-01 Pablo Cassara Srl Lab A PHARMACEUTICAL FORMULATION IN ADEQUATE AEROSOL FOR ORAL OR NASAL INHALATION CONTAINING GLUCOCORTICOIDS IN A STABLE SOLUTION TO STORAGE; A METHOD FOR STABILIZING FORMULATIONS AND USE OF A STABILIZING AGENT
US20050238632A1 (en) * 2004-04-23 2005-10-27 Alburty David S Propellant formulations
ES2257152B1 (en) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. COMBINATIONS THAT INCLUDE ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS.
AU2005259523B2 (en) * 2004-07-02 2011-06-09 Boehringer Ingelheim International Gmbh Aerosol suspension formulations containing TG 227 ea or TG 134 a as a propellant
GB0417481D0 (en) * 2004-08-05 2004-09-08 Etiologics Ltd Combination therapy
US9084799B2 (en) 2005-02-11 2015-07-21 Pulmagen Therapeutics (Synergy) Limited Inhaled combination therapy
US8431553B2 (en) 2005-02-11 2013-04-30 Pulmagen Therapeutics (Synergy) Limited Combination of methylxanthine compounds and steroids to treat chronic respiratory diseases
DE102006017320A1 (en) 2006-04-11 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosol suspension formulations with TG 227 ea or TG 134 a as propellant
US20070286814A1 (en) * 2006-06-12 2007-12-13 Medispray Laboratories Pvt. Ltd. Stable aerosol pharmaceutical formulations
US8148377B2 (en) 2007-02-11 2012-04-03 Map Pharmaceuticals, Inc. Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
RU2504402C1 (en) * 2012-11-20 2014-01-20 Шолекс Девелопмент Гмбх Inhalation formulation in form of aerosol for treating bronchial asthma and chronic obstructive pulmonary disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI63672C (en) * 1980-05-19 1983-08-10 Orion Yhtymae Oy FOERFARANDE FOER FRAMSTAELLNING AV EN BLANDNING AV BEKLOMETASONDIPROPIONAT OCH TRIKLORFLUORMETAN ELLER DIKLORDIFLUORMETAN
KR890000664B1 (en) * 1981-10-19 1989-03-22 바리 안소니 뉴우샘 Preparation method for micronised be clomethasone dispropionate mono-hydrate
GB2107715B (en) * 1981-10-19 1985-11-13 Glaxo Group Ltd Micronised beclomethasone dipropionate monohydrate and powder inhalation compositions containing it
GB8432063D0 (en) * 1984-12-19 1985-01-30 Riker Laboratories Inc Physically modified steroids
WO1992006675A1 (en) * 1990-10-18 1992-04-30 Minnesota Mining And Manufacturing Company Aerosol formulation comprising beclomethasone 17,21 dipropionate

Similar Documents

Publication Publication Date Title
RU94040361A (en) AEROSOL PHARMACEUTICAL COMPOSITION, SPRAYER FOR DELIVERY OF THE COMPOSITION, DOSAGE INHALATOR, METHOD FOR TREATING RESPIRATORY DISEASES, METHOD FOR PRODUCING THE COMPOSITION
DE69523587T2 (en) Fluticasone propionate FORMULATIONS
DE69526517T2 (en) FUEL GAS MIXTURE FOR AEROSOL PREPARATION
EP1143931B1 (en) Pulmonary drug delivery
EP0920302B2 (en) Pharmaceutical aerosol composition
CA2353959C (en) A medicinal aerosol formulation
JP5599961B2 (en) Pharmaceutical composition
EP0588897B1 (en) Non-chlorofluorocarbon aerosol formulations
DE69233076T2 (en) aerosol preparations
EP0918507B2 (en) Aerosol formulations
EP0587790B1 (en) Non-chlorofluorocarbon aerosol formulations
US20010031244A1 (en) Pharmaceutical aerosol composition
RU98118908A (en) PHARMACEUTICAL DELIVERY CYLINDER, DOSING INHALER
MY108748A (en) Medicaments
RU2006112589A (en) PHARMACEUTICAL COMPOSITIONS FOR TREATING PREMATURE EJACULATION USING PULMONARY INHALATION
WO2000047203A1 (en) Formulation and system for intra-oral delivery of pharmaceutical agents
GR3018168T3 (en) Medicaments.
RS49803B (en) Use of aqueous medicament prepara tions for the production of propellent gas-free aerosols
CA2125666A1 (en) Medicaments
HU226694B1 (en) Medicinal aerosol products containing ciclesonide
JPH07103043B2 (en) Calcitonin composition and uses thereof
EP0630229A1 (en) Pressurized gas packagings using polyoxyethylene glyceryl-obates.
O Callaghan et al. The history of inhaled drug therapy
US3608065A (en) Aerosol composition containing a vasoconstrictor
GB1333767A (en) Pharmaceutical compositions for inhalation comprising n-isopropyl noratropinium methylate salts